Autoimmuneinflammatory

Autoimmuneinflammatory is not a standard diagnostic label but denotes diseases where autoimmunity drives tissue inflammation through adaptive immune responses, capturing overlap between autoimmune mechanisms and inflammatory pathways.

Pathophysiology involves autoantibodies, autoreactive T cells, immune complexes, and cytokines (TNF, IL-1, IL-6, IFN). Genetic susceptibility and environmental triggers contribute; epitope spreading and molecular mimicry can perpetuate inflammation.

Conditions with autoimmuneinflammatory features include rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, multiple sclerosis, psoriasis, and type 1 diabetes. These diseases commonly show chronic inflammation with autoantibody or autoreactive T-cell involvement.

Diagnosis relies on clinical presentation, laboratory markers (CRP, ESR), autoantibody testing (ANA, RF, anti-dsDNA, anti-CCP), and imaging or tissue biopsy as needed. Distinguishing from autoinflammatory disorders focuses on adaptive immunity involvement, though overlap exists.

Management targets immune modulation and inflammation. Treatments include conventional DMARDs (methotrexate, azathioprine, mycophenolate), corticosteroids, and biologics (TNF inhibitors, IL-6 receptor antagonists, B-cell agents). Therapy is individualized to balance efficacy and infection risk.

Terminology varies; the concept emphasizes shared inflammatory pathways across autoimmune diseases. Ongoing research seeks biomarkers, better classification, and personalized therapies.